Decitabine + Decitabine

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pediatric Acute Myelogenous Leukemia (AML)

Conditions

Pediatric Acute Myelogenous Leukemia (AML)

Trial Timeline

Mar 3, 2011 → Jul 19, 2013

NCT ID

NCT01177540

About Decitabine + Decitabine

Decitabine + Decitabine is a phase 2 stage product being developed by Eisai for Pediatric Acute Myelogenous Leukemia (AML). The current trial status is terminated. This product is registered under clinical trial identifier NCT01177540. Target conditions include Pediatric Acute Myelogenous Leukemia (AML).

What happened to similar drugs?

3 of 19 similar drugs in Pediatric Acute Myelogenous Leukemia (AML) were approved

Approved (3) Terminated (0) Active (16)

✅Boosted AtazanavirBristol Myers SquibbApproved

✅Atazanavir + RitonavirBristol Myers SquibbApproved

✅IgPro10CSLApproved

🔄candsartan cilexetilAstraZenecaPhase 3

🔄basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroidsNovartisPhase 3

🔄VAL489 + VAL489 matching placeboNovartisPhase 3

🔄Entecavir + Lamivudine + Pegylated Interferon Alfa-2ARochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01177540	Phase 2	Terminated	Mar 3, 2011	Jul 19, 2013	Pediatric Acute Myelogenous Leukemia (AML)
NCT00619099	Phase 2	Completed	May 1, 2008	—	Myelodysplastic Syndrome

Competing Products

20 competing products in Pediatric Acute Myelogenous Leukemia (AML)

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab	Eli Lilly	Phase 1	29
erlotinib + etoposide	Astellas Pharma	Phase 2	27
Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine	Sun Pharmaceutical	Phase 1	33
Perampanel Oral Suspension + Perampanel Tablet	Eisai	Phase 2	42
Eribulin Mesylate	Eisai	Phase 1	29
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily	Sumitomo Pharma	Phase 1	29
Remimazolam Tosilate for injection + Propofol Injection	Jiangsu Hengrui Medicine	Phase 2/3	45
Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid	AstraZeneca	Phase 2/3	38
candsartan cilexetil	AstraZeneca	Phase 3	40
Durvalumab / Tremelimumab Combination Therapy	AstraZeneca	Phase 1/2	36
Rotavirus Vaccine	Merck	Pre-clinical	18
basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids	Novartis	Phase 3	40
VAL489 + VAL489 matching placebo	Novartis	Phase 3	40
LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696	Novartis	Phase 2/3	38
Everolimus	Novartis	Phase 2	35
Corticosteroids + Cyclosporine + mycophenolate mofetil	Roche	Phase 2	27
Entecavir + Lamivudine + Pegylated Interferon Alfa-2A	Roche	Phase 3	40
Blinatumomab for Injection	Amgen	Phase 1	25
Etanercept	Amgen	Phase 3	40
Denosumab	Amgen	Phase 3	40